The present invention relates to dual GLP-1 / glucagon receptor agonists, and to medical uses thereof, for example in the treatment of disorders of metabolic syndrome, including diabetes and obesity, as well as for reducing excessive food intake.マルティンボザート...
Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetesDual GIP/GLP-1 receptor agonistglucagon-like peptide-1 (GLP-1)glucose-dependent insulinotropic polypeptide (GIP)...
Glucagon-like peptide 1 (GLP-1) is a peptide hormone and growth factor. Cholecystokinin (CCK) is another peptide hormone, growth factor and neurotransmitter. Both peptide hormones have shown good neuroprotective effects in animal models of Alzheimer's disease (AD). In this study, we tested the...
Glucagon-like peptide-1 (GLP-1) is an incretin peptide hormone mainly secreted by enteroendocrine intestinal L-cells. GLP-1 is also secreted by α-cells of the pancreas and the central nervous system (CNS). GLP-1 secretion is stimulated by nutrient intak
Activation of the glucagon-like peptide 1 (GLP-1) receptor has been shown to decrease glucose, reduce appetite, lower body weight, and improve insulin sensitivity in patients with type 2 diabetes, obesity, or both. Se...
YH25724, a novel long-acting GLP-1/FGF21 dual agonist provides potent and sustained glycaemic control, body weight loss and lipid profile improvement in animal models H.N. Hong, J.H. Kim, H.H. Choi, D. Kim, S. Lim, M. Seo, M.K. Ju, J.Y. Park, B.H. Choi, J.G. Kim, ...
(2024) 16:264 Diabetology & Metabolic Syndrome RESEARCH Open Access Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta- analysis of randomized controlled trials Haijun Wan1, Nuo Xu1, Lijuan Wang1, Yaping Liu2, Somaye Fatahi3, Mohammad ...
This chimeric structure distinguishes them from a separate class of dual- or tri- agonist molecules in which conjugation strategies involv- ing synthetic linker chemistry are used to fuse the full-length amino acid sequences of peptides such as the hor- mones glucagon, GLP-1, gastrin, and ...
Broadly, the present invention relates to compounds which have agonist activity at the GLP-1 (glucagon-like peptide 1) and GLP-2 (glucagon-like peptide 2) receptors, e.g. as assessed in in vitro potency assays. Such compounds are referred to in this specification as “GLP-1/GLP-2 dual ...
The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia,